Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

Mounting evidence supports a role for the immune system in breast cancer outcomes. The ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from weakly immunogenic or inherently immune-resistant tumors would guide development of therapeutic strategies in breast cancer....

Full description

Bibliographic Details
Main Authors: Alexandra Thomas, Eric D. Routh, Ashok Pullikuth, Guangxu Jin, Jing Su, Jeff W. Chou, Katherine A. Hoadley, Cristin Print, Nick Knowlton, Michael A. Black, Sandra Demaria, Ena Wang, Davide Bedognetti, Wendell D. Jones, Gaurav A. Mehta, Michael L. Gatza, Charles M. Perou, David B. Page, Pierre Triozzi, Lance D. Miller
Format: Article
Language:English
Published: Taylor & Francis Group 2018-10-01
Series:OncoImmunology
Subjects:
breast cancer
mutational burden
immune subtypes
prognosis
survival
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1490854

Internet

http://dx.doi.org/10.1080/2162402X.2018.1490854

Similar Items